Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key Studies in Genitourinary Cancers: CCO Independent Conference Highlights of the 2021 ASCO Annual Meeting
  • CME

Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS
Released: September 7, 2021

Final Thoughts on Other Key Genitourinary Cancer Studies

Other Key GU Studies at ASCO 2021

Daniel P. Petrylak, MD:
Aside from the studies we covered, Johann de Bono30 presented interesting data on HPN424a, a PSMA-targeting T-cell engager. The researchers reported some soft tissue responses and PSA declines. It is a completely new approach, and I find it very exciting.

Elizabeth R. Plimack, MD, MS:
I also am very excited about those trials, along with the other trials we discussed here.

Daniel P. Petrylak, MD:
I am worried that the COVID-19 pandemic has slowed down clinical trial accrual, and that may slow down what we are able to learn and present over the next few years, but I think the science during the next 10 years is going to be exciting.

Elizabeth R. Plimack, MD, MS:
I also am optimistic and think it is exciting to look back at how far the field has come for treating patients with genitourinary cancers to improve the outcomes and OS for our patients.

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings